20 Phase‑3 Trials Poised to Redefine Cancer Care
In the wake of the #ASCO26 data drop, we reflect on 20 key phase 3 trials which could make a significant impact. Some of these may make their competitors irrelevant if they change the standard of care: https://t.co/EGtw35EsSk https://t.co/CG0Oe4QxDg
Genomics Predict Venetoclax Response in T(
Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax [Dec 7, 2024] @MKaddouraMD et al. @lbaughn #ASH24 Abst 249 https://t.co/TLon5bCQ3i #mmsm #PrecisionMedicine
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex for Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc
Kelun's MRK ADC Shows Promise Over Akeso in Lung Cancer
The #ASCO26 abstracts are live. I wrote a story about the Kelun $MRK ADC sac-TMT, which looks very good in lung cancer, potentially better than Akeso / $SMMT 's ivonescimab https://t.co/exfmgabTLa
WTHealth Podcast Explores Senate HELP Future, Ebola, Insurance Denials
New #WTHealth podcast up: @SherylNYT, @AliceOllstein, @JoanneKenen on what's next for the Senate HELP committee, the latest on ebola, and more shakeups at HHS. Also an interview with @mirandayaver on her book on insurance denials. https://t.co/j57hHvfz9Y
Your Step‑by‑Step Guide to Health Equity Accreditation
Wondering what health equity accreditation really involves? From readiness assessments to data strategy, this guide breaks down the full process. 👉 https://t.co/EGVUOfJbVQ @URAC #HealthEquityData #HITSM
Clinicians Favor MRD‑guided Decisions in Myeloma Care
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] @bdermanmd @ajjakubowiak @mtmdphd @BloodCancerJnl https://t.co/idtv0bQtNB #mmMRD #mmsm #openaccess https://t.co/YyGkqFHeC9
First FDA‑approved Longevity Drug Targets Dogs First
NEW Exclusive Interview: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal @celinehalioua is building the first drug ever FDA-approved for lifespan extension itself — starting with dogs. We sat down on Onward to...
Acting NIH Infectious Disease Institute Head Resigns
Acting head of NIH’s infectious disease institute reported to have stepped down via @HelenBranswell @AnilOza16 https://t.co/YiUgVJpHb3
Cedars Sinai Deploys Live Patient‑Context AI for Clinical Decision Support
Cedars Sinai clinicians are the FIRST to use OpenEvidence to integrate live patient context from Epic and access personalized CDS AI. My 6 thoughts on what this means for the industry: First, the gist of what was announced: → Clinicians can ask...
Retatrutide Delivers up to 30% Weight Loss in Phase 3 Trials
Retatrutide just delivered some very impressive phase3 results for $LLY at 4mg, 9mg and 12mg -- https://t.co/7sKbaDoInq Retatrutide is their GLP-3 ie triple agonist which hits the GLP, GIP and Glucagon receptors. At the primary endpoint of 80 weeks... patients on 4mg,...
Primary Care Lacks Mental Health Training, Fueling Deaths
Primary care doctors handle 75 percent of all mental health care in this country. They receive 2 percent of their total training in it. That is not a resource gap. It is a curriculum failure that has not changed in...
FDA Turnover Delays Rare Disease Drug Development, Experts Warn
Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development https://t.co/H3z7G2kQyc via @statnews
IL-6 Blocker Shows Promise for Treating Depression
Would depression respond to an anti-inflammation drug (interleukin-6 blocker)? A small pilot, placebo-controlled randomized trial suggests this might be possible https://t.co/zKO76yvRAo https://t.co/e8K9YLEAQj
AI Scans Enable Decade‑long Primary Disease Prevention for High‑risk Patients
Using AI of a medical scan to achieve primary prevention of disease over the next decade in people at high-risk @ScienceTM https://t.co/inpvk55qBA https://t.co/3awSGlBjuK
ASCO Abstracts Posted Tomorrow, Full Data Saved for Meeting
The #ASCO26 abstracts will be posted tomorrow at 5 pm EDT. What this means, and what is doesn't. -- No late-breaker abstracts tomorrow. You will not see the plenary session data from $RVMD, Akeso / $SMMT, $JNJ or $LLY....
Parabilis Raises $800M, Eyes IPO to Tackle Undruggable Targets
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets https://t.co/hKprr9rkJ4 @ByJonGardner $PBLS #biotech #IPO
Lithium Cholesterol Sulfate Shows Promise for Alzheimer’s and Autism
Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder https://t.co/RtPZtiGG8k
BARDA Ships Experimental Ebola Antibody to Protect High‑risk Americans
BARDA is coordinating shipment of an experimental antibody treatment for potential use in high-risk Americans exposed to #ebola, HHS tells CNN While they didn't name the treatment, Mapp's MBP134 has shown activity in animal studies against Bundibugyo strain
FDA Review Highlights Single‑Arm Trial Approval Risks
$IBRX -- The FDA accepted the sBLA to expand Anktiva to include the treatment of MNBIC papillary. The PDUFA date is Jan. 6, 2027. Standard review. A positive development for ImmunityBio, but like all things, details matter. Approval...
Epic Moves to Dismiss Disability Access Lawsuit
Epic finally filed their Motion to Dismiss in American Association for Disability Justice v. Epic. As a reminder, if you’re forgetting that particular lawsuit, it was structured around the premise: …𝘵𝘩𝘢𝘵 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘺’𝘴 𝘢𝘳𝘤𝘩𝘪𝘵𝘦𝘤𝘵𝘶𝘳𝘦 𝘧𝘰𝘳 𝘢𝘤𝘤𝘦𝘴𝘴𝘪𝘯𝘨 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘤𝘰𝘳𝘥𝘴 (𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳𝘭𝘺 𝘪𝘵𝘴 𝘳𝘦𝘭𝘪𝘢𝘯𝘤𝘦...
AI‑crafted Sensors Promise Earlier Cancer Detection
#AI-generated #Sensors open new paths for early cancer detection by Anne Trafton @MIT Learn more: https://t.co/udkbd5V4cP #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/6EWRhwCIGA
AI Tool Guides Doctors to Treat Newborn’s Rare Disease
How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’ An AI tool, Biomedical Data Translator, helped doctors at Mayo Clinic find a treatment for Jorie Kraus https://t.co/3qs1WIDquU
Aid Cuts Fuel DRC Ebola Surge, Hindering Control
NEW: The Trump admin's foreign aid cuts have hampered infection control in the DRC as the country's Ebola outbreak grows, people involved across the region tell me https://t.co/BpAnbXcsYh
ACA Deductibles Surge $1,000 as Subsidies End
New: The average ACA deductible has jumped by over $1,000 per person in 2026 as people switched to lower premium plans with higher deductibles as Congress allowed enhanced premium subsidies to expire.
AI Scribes: Hype vs Proven Efficiency in Healthcare
I used 𝑠𝑐𝑒𝑛𝑎𝑟𝑖𝑜 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠 to analyze the near future of AI scribes in their promise of replacing administration. Key driver: Growing evidence in studies Major uncertainty: Acceptance by medical professionals 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨 #𝟏. 𝐃𝐚𝐧𝐠𝐞𝐫𝐨𝐮𝐬 𝐇𝐲𝐩𝐞 (𝐇𝐢𝐠𝐡 𝐚𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 / 𝐋𝐨𝐰 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞) Clinicians adopt AI scribes enthusiastically...
AR‑AI System Cuts Brain Surgery Errors, Saves Millions
Just met with @camrooahmed who has built a system for brain surgeons that uses augmented reality and AI to more accurately display brain tumors. Done about 100 surgeries already and mistake rates go way down, which saves massive amounts of...
More Prep, Fewer Depressive Symptoms in Psychedelic Therapy
More psychological prep, better outcomes: Psychological Therapy Quantity and Depressive Symptoms in Psychedelic Therapy https://t.co/akdzksV59W
Urgent Need for Ebola Bundibugyo Vaccine Development
This is the kind of work, published today, that should be fully supported and prioritized at the highest level. Currently, there is no vaccine vs the Ebola Bundibugyo virus, the source of a major outbreak https://t.co/qM6bWLtmcb https://t.co/IJ7lVXKQNX
Kazia’s Paxalisib Shows >50% CTC Drop, Early Responses
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on upcoming ASCO data from their Paxalisib drug development platform. The update is following earlier disclosures from their ongoing Phase 1b ABC-Pax study evaluating paxalisib in metastatic triple-negative breast cancer (TNBC) showing...
Merck's China-Licensed ADC Succeeds in First Global Trial
Merck ADC, licensed from China, hits mark in first big global trial https://t.co/tAvLkw6pYm @ByJonGardner $MRK $GILD $AZN
Procedural Notes Aren’t Generic Data—Misclassify at Your Peril
Procedural notes drive safety, throughput, coding, and revenue. Treating them like generic data is a costly mistake. Important read from @Provationmed on the hidden risks CIOs face when changing clinical documentation platforms. https://t.co/WahjLaUB6N #ClinDoc #HITSM
AI Uses One MRI and Demographics to Forecast Alzheimer’s Cognition
A single MRI + demographics + AI predicts current and future cognitive scores and outcomes for Alzheimer’s disease https://t.co/9Mm3kOCI8L
Once‑night Pill Proves Effective for Severe Sleep Apnea
A once a night pill for severe obstructive sleep apnea effective in a Phase 3 randomized trial https://t.co/zq2Ew65WHK https://t.co/ovQEh7taeN https://t.co/N8vXzYincy
2025 Gene Therapy Sales: New Top 10 Entrants Revealed
18May: Which were the Top 10 Best-Selling Gene Therapies based on 2025 sales? Which gene therapies made this year's list but missed last year's, and vice versa? Check out my latest A-List for @GENbio: https://t.co/pbUP8lI82X
Zusduri Demonstrates Real-World Efficacy for Low-Grade UTUC
UroGen’s Zusduri shows strong real-world results for low-grade upper tract urothelial cancer, matching clinical trial efficacy. A promising kidney-sparing option, though durability and reimbursement remain key hurdles. Urology
Postpartum Deaths Surge: U.S. Lacks Home Care Support
60 percent of maternal deaths happen after a woman gives birth. The U.S. system sends mothers home from delivery and schedules the next appointment six weeks later. In those six weeks, a mother manages a healing body, a newborn, often...
WHO Declares Bundibugyo Ebola Outbreak a PHEIC
1. #WHO has declared the #Ebola #Bundibugyo outbreak in NE DRC a public health emergency of international concern, aka a PHEIC. Yet another sign this is likely to be a very challenging outbreak. So far there've been 8 confirmed cases, 246...
AI and Nurse Practitioners Together Amplify Healthcare Potential
Interesting, timely article on ascendancy of NPs; remarkable parallels (pro & con) w arguments around MDs and AI. MDs say a good doc is best; AI/NP champions say available AI/NP>fantasy of Marcus Welby. https://t.co/wZCH6QBL4y ofc, AI+NP=even more promising? @zakkohane
CRISPR Shifts to DNA‑guided RNA Targeting
Expanding the CRISPR genome editing toolkit: A flip from RNA-guided DNA targeting to DNA-guided RNA targeting @NatureBiotech https://t.co/GxKVthgbxh https://t.co/UIifna0nsF https://t.co/2ZB1eJzpCe
Polyphenol‑rich Foods Slow Cardiovascular Aging
Berries, Tea, Coffee - and a Slower Cardiovascular Aging Curve As a medical school professor, I teach that cardiovascular risk climbs with age. What I am updating is how much of that climb is negotiable. A 10-year study from King's College London,...
Getting Through the Door Beats Pain as Patient Barrier
Why your patient’s biggest barrier isn’t pain. It’s walking through the door. [PODCAST] http://dlvr.it/TSZ7FS Podcast #PrimaryCare
Humans and Axolotls Share Key Regeneration Genes
Humans and Axolotls Share Many Regeneration-Related Genes Scientists have found that humans and axolotls share many of the same genes and molecular pathways involved in limb development and tissue regeneration. Axolotls activate these pathways as adults to...
Faster Biological Aging Linked to Higher Cardiovascular Risk
Association between accelerated biological aging and major adverse cardiovascular events in patients with stable coronary artery disease https://t.co/KOy0EElZQe
Antibody‑Drug Conjugates Surge in Cancer Clinical Research
The progress and intensity of clinical research efforts with antibody-drug conjugates vs cancer is remarkable A new @CellCellPress review https://t.co/bkaJ2OOt63
LLMs in EHRs Enable Earlier Cancer Risk Detection
We could pick up risk of cancer and detect it much earlier if we applied LLMs to electronic health records, as shown in this @AllofUsResearch study https://t.co/VBFxeOWZAz
Successful Hookworm Vaccine Trials Aim for Global Low‑Cost Scale
No need to bother our friend @grok the answer is yes, our vaccine group was funded by Gates Foundation for a hookworm anemia vaccine although the funding stopped a decade ago. But we just published in @TheLancetInfDis that the vaccine...
Insurers Push Rural Patients Into Unsafe Off‑Site Chemo
A private insurer just decided that a cancer patient could not have her chemotherapy in the cancer center. She walked away from treatment entirely. This is the rollout most clinicians have not noticed yet, and it is starting in rural...
Anshar AI Cuts Prior Auth From Hours to Minutes
What if prior auth didn’t take 10 hours—but minutes? Anshar AI is applying agentic AI to one of healthcare’s biggest bottlenecks. Check out the interview. ⬇️ https://t.co/LPxKHPOWGk #AnsharAI #RCM #HIMSS26 #HITSM
Multimodal AI Beats Physicians on 29 of 32 Metrics
A multimodal AI (AIME) had superior performance compared with 18 physicians for almost every metric (29 of 32 axes). Randomized, but simulated, not real-world clinical practice. @GoogleDeepMind @alan_karthi @RyutaroTanno https://t.co/PIs9VZmlMi https://t.co/nDC8p2jmus